Head to Head Survey: Adhera Therapeutics (OTCMKTS:ATRX) vs. Grace Therapeutics (NASDAQ:GRCE)

Grace Therapeutics (NASDAQ:GRCE) and Adhera Therapeutics (OTCMKTS:ATRX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Grace Therapeutics and Adhera Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-17.47%	-15.89%
Adhera Therapeutics	N/A	N/A	N/A

Earnings and Valuation

This table compares Grace Therapeutics and Adhera Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$9.57 million	($0.62)	-5.66
Adhera Therapeutics	N/A	N/A	N/A	($1.15)	0.00

Grace Therapeutics is trading at a lower price-to-earnings ratio than Adhera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

6.1% of Grace Therapeutics shares are held by institutional investors. 11.1% of Grace Therapeutics shares are held by company insiders. Comparatively, 28.2% of Adhera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and target prices for Grace Therapeutics and Adhera Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1	0	2	0	2.33
Adhera Therapeutics	0	0	0	0	0.00

Grace Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 241.88%. Given Grace Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Grace Therapeutics is more favorable than Adhera Therapeutics.

Risk and Volatility

Grace Therapeutics has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Adhera Therapeutics has a beta of 12.01, meaning that its stock price is 1,101% more volatile than the S&P 500.

About Grace Therapeutics

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

About Adhera Therapeutics

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.